Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis

Hajnalka Jókai, József Szakonyi, Orsolya Kontár, Gábor Barna, Dóra Inotai, Sarolta Kárpáti, Péter Holló

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

A considerable number of patients with psoriasis show secondary resistance during long-term TNF-alpha inhibitor therapy, necessitating the identification of reliable predictive markers. Predictive role of cutaneous lymphocyte-associated antigen (CLA) was investigated. Thirty-eight severe patients with psoriasis were treated for a 24-week-long study period. Clinical responsiveness (PASI) and changes in flow cytometry-measured peripheral lymphocyte CLA expression (week 0-2-6) were statistically analysed. Regarding 24-week-long treatment outcome patients were divided into two groups: During the first 6 weeks, mean CLA expression showed significant (P = 0.034604) increase among responders (32/38), while after a preliminary increase, it was significantly (P = 0.012539) decreasing in the relapsing group (6/38). Pearson's correlation analysis showed significant negative correlation between PASI and CLA changes. Responders showed (not significantly) lower initial CLA expression than relapsing patients. Our observations suggest change in CLA expression during the first 6 weeks of induction period to serve as a potential predictive marker of TNF-alpha inhibitor therapy in psoriasis.

Original languageEnglish
Pages (from-to)221-223
Number of pages3
JournalExperimental Dermatology
Volume22
Issue number3
DOIs
Publication statusPublished - Mar 2013

Fingerprint

Biological Therapy
Lymphocytes
Psoriasis
Tumor Necrosis Factor-alpha
Antigens
Skin
Patient treatment
Flow cytometry
Flow Cytometry
Therapeutics

Keywords

  • Cutaneous lymphocyte-associated antigen
  • Predictive marker
  • Psoriasis vulgaris
  • TNF-alpha inhibitors

ASJC Scopus subject areas

  • Dermatology
  • Molecular Biology
  • Biochemistry

Cite this

Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis. / Jókai, Hajnalka; Szakonyi, József; Kontár, Orsolya; Barna, Gábor; Inotai, Dóra; Kárpáti, Sarolta; Holló, Péter.

In: Experimental Dermatology, Vol. 22, No. 3, 03.2013, p. 221-223.

Research output: Contribution to journalArticle

Jókai, Hajnalka ; Szakonyi, József ; Kontár, Orsolya ; Barna, Gábor ; Inotai, Dóra ; Kárpáti, Sarolta ; Holló, Péter. / Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis. In: Experimental Dermatology. 2013 ; Vol. 22, No. 3. pp. 221-223.
@article{002f9f394e04428886f0f4e1a6c63aca,
title = "Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis",
abstract = "A considerable number of patients with psoriasis show secondary resistance during long-term TNF-alpha inhibitor therapy, necessitating the identification of reliable predictive markers. Predictive role of cutaneous lymphocyte-associated antigen (CLA) was investigated. Thirty-eight severe patients with psoriasis were treated for a 24-week-long study period. Clinical responsiveness (PASI) and changes in flow cytometry-measured peripheral lymphocyte CLA expression (week 0-2-6) were statistically analysed. Regarding 24-week-long treatment outcome patients were divided into two groups: During the first 6 weeks, mean CLA expression showed significant (P = 0.034604) increase among responders (32/38), while after a preliminary increase, it was significantly (P = 0.012539) decreasing in the relapsing group (6/38). Pearson's correlation analysis showed significant negative correlation between PASI and CLA changes. Responders showed (not significantly) lower initial CLA expression than relapsing patients. Our observations suggest change in CLA expression during the first 6 weeks of induction period to serve as a potential predictive marker of TNF-alpha inhibitor therapy in psoriasis.",
keywords = "Cutaneous lymphocyte-associated antigen, Predictive marker, Psoriasis vulgaris, TNF-alpha inhibitors",
author = "Hajnalka J{\'o}kai and J{\'o}zsef Szakonyi and Orsolya Kont{\'a}r and G{\'a}bor Barna and D{\'o}ra Inotai and Sarolta K{\'a}rp{\'a}ti and P{\'e}ter Holl{\'o}",
year = "2013",
month = "3",
doi = "10.1111/exd.12093",
language = "English",
volume = "22",
pages = "221--223",
journal = "Experimental Dermatology",
issn = "0906-6705",
publisher = "Wiley-Blackwell",
number = "3",

}

TY - JOUR

T1 - Cutaneous lymphocyte-associated antigen as a novel predictive marker of TNF-alpha inhibitor biological therapy in psoriasis

AU - Jókai, Hajnalka

AU - Szakonyi, József

AU - Kontár, Orsolya

AU - Barna, Gábor

AU - Inotai, Dóra

AU - Kárpáti, Sarolta

AU - Holló, Péter

PY - 2013/3

Y1 - 2013/3

N2 - A considerable number of patients with psoriasis show secondary resistance during long-term TNF-alpha inhibitor therapy, necessitating the identification of reliable predictive markers. Predictive role of cutaneous lymphocyte-associated antigen (CLA) was investigated. Thirty-eight severe patients with psoriasis were treated for a 24-week-long study period. Clinical responsiveness (PASI) and changes in flow cytometry-measured peripheral lymphocyte CLA expression (week 0-2-6) were statistically analysed. Regarding 24-week-long treatment outcome patients were divided into two groups: During the first 6 weeks, mean CLA expression showed significant (P = 0.034604) increase among responders (32/38), while after a preliminary increase, it was significantly (P = 0.012539) decreasing in the relapsing group (6/38). Pearson's correlation analysis showed significant negative correlation between PASI and CLA changes. Responders showed (not significantly) lower initial CLA expression than relapsing patients. Our observations suggest change in CLA expression during the first 6 weeks of induction period to serve as a potential predictive marker of TNF-alpha inhibitor therapy in psoriasis.

AB - A considerable number of patients with psoriasis show secondary resistance during long-term TNF-alpha inhibitor therapy, necessitating the identification of reliable predictive markers. Predictive role of cutaneous lymphocyte-associated antigen (CLA) was investigated. Thirty-eight severe patients with psoriasis were treated for a 24-week-long study period. Clinical responsiveness (PASI) and changes in flow cytometry-measured peripheral lymphocyte CLA expression (week 0-2-6) were statistically analysed. Regarding 24-week-long treatment outcome patients were divided into two groups: During the first 6 weeks, mean CLA expression showed significant (P = 0.034604) increase among responders (32/38), while after a preliminary increase, it was significantly (P = 0.012539) decreasing in the relapsing group (6/38). Pearson's correlation analysis showed significant negative correlation between PASI and CLA changes. Responders showed (not significantly) lower initial CLA expression than relapsing patients. Our observations suggest change in CLA expression during the first 6 weeks of induction period to serve as a potential predictive marker of TNF-alpha inhibitor therapy in psoriasis.

KW - Cutaneous lymphocyte-associated antigen

KW - Predictive marker

KW - Psoriasis vulgaris

KW - TNF-alpha inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84875052028&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84875052028&partnerID=8YFLogxK

U2 - 10.1111/exd.12093

DO - 10.1111/exd.12093

M3 - Article

VL - 22

SP - 221

EP - 223

JO - Experimental Dermatology

JF - Experimental Dermatology

SN - 0906-6705

IS - 3

ER -